/
CHRS
$1.14-$0.03 (-2.56%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$180.8M
155M shares
52-week range
$0.95 – $2.62
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-12.90
Coherus Oncology, Inc. Common Stock
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
www.coherus.com- Employees
- 144
- IPO / List date
- Nov 6, 2014
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds CHRS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 331,700 | $560.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CHRS yet.
